About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

49.20 -0.83 (-1.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Via ACCESS Newswire
News headline image
3 Stocks Under $50 with Warning Signs
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
Moderna Inc (NASDAQ:MRNA) Beats Q4 2025 Estimates Amid Post-Pandemic Transition ↗
Via Chartmill
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Shopify's Whiplash Day ↗
It looked like Shopify's stock was headed for a great day when it reported earnings, only for the stock to give up all its gains and then some when management started talking on the conference call. 
Via The Motley Fool
News headline image
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
Via ACCESS Newswire
News headline image
3 Cash-Burning Stocks That Fall Short
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
Via StockStory
Topics Bankruptcy
News headline image
MRNA Q4 Deep Dive: New Vaccines, Cost Controls, and Pipeline Milestones Shape Outlook
Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its non-GAAP loss of $2.11 per share was 20.2%... 
Via StockStory
News headline image
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results
Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s... 
Via MarketMinute
Topics Earnings
News headline image
Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
Top S&P500 movers in Friday's session ↗
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Moderna (MRNA) Q4 2025 Earnings Call Transcript ↗
Moderna (MRNA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Moderna (NASDAQ:MRNA) Exceeds Q4 CY2025 Expectations
Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its GAAP loss of $2.11 per share was 18.9% above... 
Via StockStory
Topics Artificial Intelligence
News headline image
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
Via ACCESS Newswire
News headline image
Nasdaq, S&P 500 Futures Edge Lower Ahead Of CPI Data: Why NVDA, AAPL, TSLA, RIVN, MRNA, AMAT, IREN Are On Traders' Radar Today ↗
Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ. 
Via Stocktwits
Topics Bonds ETFs Economy
News headline image
Moderna: Stock to Avoid or Bad News Buy? ↗
Moderna stock was a highflier in early pandemic days as sales of its coronavirus vaccine soared. 
Via The Motley Fool
News headline image
FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%
Shares of Moderna, Inc. (NASDAQ: MRNA) fell 3.5% on February 12, 2026, as investors continued to digest the fallout from a rare and unexpected regulatory setback. The U.S. Food and Drug Administration... 
Via MarketMinute
Topics Earnings
News headline image
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of... 
Via Finterra
Topics Initial Public Offering Intellectual Property
AI Agents and the Jobs Report Jitter: A Wall Street Balancing Act ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
What To Expect From Moderna’s (MRNA) Q4 Earnings
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before market hours. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
Gapping S&P500 stocks in Wednesday's session ↗
Via Chartmill
News headline image
Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical... 
Via Finterra
Topics Artificial Intelligence Initial Public Offering Intellectual Property
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Rise Ahead Of Delayed Jobs Data: Why NVDA, WBD, HOOD, MRNA, ASTS Are On Traders' Radar Today ↗
Retail chatter on Stocktwits shows that sentiment remains deeply bearish on SPY and QQQ. 
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
Why Did Moderna Stock Tumble Nearly 10% After Hours Today? ↗
The FDA’s CBER issued a refusal-to-file letter for Moderna’s flu vaccine mRNA-1010. 
Via Stocktwits
News headline image
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.